The Boston Sickle Cell Center is structured into five (5) main components: (1) Administration, (2) Research, (3) Testing, (4) Education and Counseling, and (5) Central Data Bank and Resource File. Through the coordinative efforts of these components the BSCC proposes to reach its specific aims as follows: 1. to sponsor and support research in the field of hemoglobinopathies conducted through our Center in five (5) major institutions in Boston: Boston University School of Medicine, Tufts-New England Medical Center, Children's Hospital Medical Center, Beth Israel Hospital and St. Elizabeth's Hospital; 2. the Center will continue to test the population """"""""at risk"""""""" for hemoglobin S gene and/or G6PD in the Boston area and will expand services to other communities where there is a population """"""""at risk""""""""; 3. the Center will begin to test for beta-thalassemia trait; 4. it will provide education and non-directive counseling to individuals identified with variant hemoglobin traits and G6PD deficiency, and counsel, support and offer direct patient services to individuals with sickle cell disease and their families; 5. it will also increase the level of awareness of knowledge about sickle cell trait and sickle cell disease within the general public through educational programs; and 6. finally it will develop and use evaluative tools to assess the effectiveness of methods used in carrying out its mission.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Comprehensive Center (P60)
Project #
5P60HL015157-18
Application #
3108424
Study Section
(SRC)
Project Start
1977-04-01
Project End
1993-03-31
Budget Start
1989-04-01
Budget End
1990-03-31
Support Year
18
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Boston Medical Center
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02118
Steinberg, Martin H; Sebastiani, Paola (2012) Genetic modifiers of sickle cell disease. Am J Hematol 87:795-803
Loscalzo, Joseph (2012) Irreproducible experimental results: causes, (mis)interpretations, and consequences. Circulation 125:1211-4
Vandorpe, David H; Xu, Chang; Shmukler, Boris E et al. (2010) Hypoxia activates a Ca2+-permeable cation conductance sensitive to carbon monoxide and to GsMTx-4 in human and mouse sickle erythrocytes. PLoS One 5:e8732
Jahangir, Eiman; Vita, Joseph A; Handy, Diane et al. (2009) The effect of L-arginine and creatine on vascular function and homocysteine metabolism. Vasc Med 14:239-48
Casula, Sabina; Zolotarev, Alexander S; Stuart-Tilley, Alan K et al. (2009) Chemical crosslinking studies with the mouse Kcc1 K-Cl cotransporter. Blood Cells Mol Dis 42:233-40
Steinberg, Martin H; Voskaridou, Ersi; Kutlar, Abdullah et al. (2003) Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease. Am J Hematol 72:121-6
Ware, Russell E; Eggleston, Barry; Redding-Lallinger, Rupa et al. (2002) Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood 99:10-4
Mirchev, R; Golan, D E (2001) Single-particle tracking and laser optical tweezers studies of the dynamics of individual protein molecules in membranes of intact human and mouse red cells. Blood Cells Mol Dis 27:143-7
Jiang, L; Jha, V; Dhanabal, M et al. (2001) Intracellular Ca(2+) signaling in endothelial cells by the angiogenesis inhibitors endostatin and angiostatin. Am J Physiol Cell Physiol 280:C1140-50
Shmukler, B E; Brugnara, C; Alper, S L (2000) Structure and genetic polymorphism of the mouse KCC1 gene. Biochim Biophys Acta 1492:353-61

Showing the most recent 10 out of 39 publications